skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 20,037  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
Results 1 2 3 4 5 next page
Refined by: Journal Title: The Lancet remove
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Towards a comprehensive public health response to population ageing
Towards a comprehensive public health response to population ageing
Material Type:
Article 		Add to My Research

Towards a comprehensive public health response to population ageing

The Lancet (British edition), 2015-02, Vol.385 (9968), p.658-661 [Peer Reviewed Journal]

World Health Organization. Published by Elsevier Ltd/Inc/BV. All rights reserved. ;2015 World Health Organization. Published by Elsevier Ltd/Inc/BV. All rights reserved. ;Copyright Elsevier Limited Feb 14, 2015 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(14)61461-6 ;PMID: 25468151 ;CODEN: LANCAO

Full text available

Citations Cited by
2
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Material Type:
Article 		Add to My Research

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

The Lancet (British edition), 2021-05, Vol.397 (10285), p.1637-1645 [Peer Reviewed Journal]

2021 Published by Elsevier Ltd. All rights reserved. This is an Open Access article under the CC BY 4.0 license ;Copyright © 2021 Published by Elsevier Ltd. All rights reserved. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. ;2021. Published by Elsevier Ltd. All rights reserved. This is an Open Access article under the CC BY 4.0 license. This work is published under https://creativecommons.org/licenses/by/3.0/ (theLicense”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2021 Published by Elsevier Ltd. All rights reserved. This is an Open Access article under the CC BY 4.0 license 2021 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(21)00676-0 ;PMID: 33933206

Full text available

Citations Cited by
3
Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data
Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data
Material Type:
Article 		Add to My Research

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

The Lancet (British edition), 2021-05, Vol.397 (10287), p.1819-1829 [Peer Reviewed Journal]

2021 Elsevier Ltd ;Copyright © 2021 Elsevier Ltd. All rights reserved. ;2021. Elsevier Ltd ;2021 Elsevier Ltd. All rights reserved. 2021 Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(21)00947-8 ;PMID: 33964222

Full text available

Citations Cited by
4
Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
Material Type:
Article 		Add to My Research

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study

The Lancet (British edition), 2021-10, Vol.398 (10309), p.1407-1416 [Peer Reviewed Journal]

2021 Elsevier Ltd ;Copyright © 2021 Elsevier Ltd. All rights reserved. ;2021. Elsevier Ltd ;2021 Elsevier Ltd. All rights reserved. 2021 Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(21)02183-8 ;PMID: 34619098

Full text available

Citations Cited by
5
COVID-19 and Italy: what next?
COVID-19 and Italy: what next?
Material Type:
Article 		Add to My Research

COVID-19 and Italy: what next?

The Lancet, 2020-04, Vol.395 (10231), p.1225-1228 [Peer Reviewed Journal]

2020 Elsevier Ltd ;Copyright © 2020 Elsevier Ltd. All rights reserved. ;2020. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.elsevier.com/legal/elsevier-website-terms-and-conditions ;2020. Elsevier Ltd ;2020 Elsevier Ltd. All rights reserved. 2020 Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(20)30627-9 ;PMID: 32178769

Digital Resources/Online E-Resources

Citations Cited by
6
Global estimates of the need for rehabilitation based on the Global Burden of Disease study 2019: a systematic analysis for the Global Burden of Disease Study 2019
Global estimates of the need for rehabilitation based on the Global Burden of Disease study 2019: a systematic analysis for the Global Burden of Disease Study 2019
Material Type:
Article 		Add to My Research

Global estimates of the need for rehabilitation based on the Global Burden of Disease study 2019: a systematic analysis for the Global Burden of Disease Study 2019

The Lancet (British edition), 2020-12, Vol.396 (10267), p.2006-2017 [Peer Reviewed Journal]

2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article published under the CC BY-NC-ND 3.0 ;Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article published under the CC BY-NC-ND 3.0 IGO license which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In any use of this article, there should be no suggestion that WHO endorses any specific organisation, products or services. The use of the WHO logo is not permitted. This notice should be preserved along with the article's original URL. ;2020. The Author(s). Published by Elsevier Ltd. This is an Open Access article published under the CC BY-NC-ND 3.0. This work is published under http://creativecommons.org/licenses/by-nc-nd/3.0/ (theLicense”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article published under the CC BY-NC-ND 3.0 2020 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(20)32340-0 ;PMID: 33275908

Full text available

Citations Cited by
7
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial
Material Type:
Article 		Add to My Research

Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

The Lancet (British edition), 2021-12, Vol.398 (10318), p.2258-2276 [Peer Reviewed Journal]

2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. ;Copyright © 2021 The Author(s). Published by Elsevier Ltd. Published by Elsevier Ltd.. All rights reserved. ;2021. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. This work is published under https://creativecommons.org/licenses/by/3.0/ (theLicense”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2021 The Author(s). Published by Elsevier Ltd. 2021 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(21)02717-3 ;PMID: 34863358

Full text available

Citations Cited by
8
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial
Material Type:
Article 		Add to My Research

Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial

The Lancet (British edition), 2020-04, Vol.395 (10232), p.1278 [Peer Reviewed Journal]

Copyright © 2020 Elsevier Ltd. All rights reserved. ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(20)30262-2 ;PMID: 32305093

Full text available

Citations Cited by
9
Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2)
Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2)
Material Type:
Article 		Add to My Research

Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2)

The Lancet (British edition), 2015-03, Vol.385 (9972), p.977-1010 [Peer Reviewed Journal]

Allemani et al. Open Access article distributed under the terms of CC BY ;2015 Allemani et al. Open Access article distributed under the terms of CC BY ;Copyright © 2015 Allemani et al. Open Access article distributed under the terms of CC BY. Published by Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Mar 14, 2015 ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(14)62038-9 ;PMID: 25467588 ;CODEN: LANCAO

Full text available

Citations Cited by
10
Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials
Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials
Material Type:
Article 		Add to My Research

Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials

The Lancet (British edition), 2016-04, Vol.387 (10029), p.1723-1731 [Peer Reviewed Journal]

Elsevier Ltd ;2016 Elsevier Ltd ;Copyright © 2016 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Apr 23, 2016 ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(16)00163-X ;PMID: 26898852 ;CODEN: LANCAO

Full text available

Citations Cited by
11
Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial
Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial
Material Type:
Article 		Add to My Research

Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial

The Lancet (British edition), 2015-07, Vol.386 (9990), p.249-257 [Peer Reviewed Journal]

Elsevier Ltd ;2015 Elsevier Ltd ;Copyright © 2015 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Jul 18, 2015 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(14)62223-6 ;PMID: 26002111 ;CODEN: LANCAO

Full text available

Citations Cited by
12
50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study
50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study
Material Type:
Article 		Add to My Research

50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study

The Lancet (British edition), 2015-07, Vol.386 (9989), p.154-162 [Peer Reviewed Journal]

Elsevier Ltd ;2015 Elsevier Ltd ;Copyright © 2015 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Jul 11, 2015 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(14)61774-8 ;PMID: 25960110 ;CODEN: LANCAO

Full text available

Citations Cited by
13
Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
Material Type:
Article 		Add to My Research

Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019

The Lancet (British edition), 2020-10, Vol.396 (10258), p.1204-1222 [Peer Reviewed Journal]

2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license ;Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. ;2020. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. This work is published under https://creativecommons.org/licenses/by/3.0/ (theLicense”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license 2020 ;ISSN: 0140-6736 ;ISSN: 1474-547X ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(20)30925-9 ;PMID: 33069326

Full text available

Citations Cited by
14
Middle East respiratory syndrome
Middle East respiratory syndrome
Material Type:
Article 		Add to My Research

Middle East respiratory syndrome

The Lancet (British edition), 2015-09, Vol.386 (9997), p.995-1007 [Peer Reviewed Journal]

Elsevier Ltd ;2015 Elsevier Ltd ;Copyright © 2015 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Sep 5, 2015 ;Copyright © 2015 Elsevier Ltd. All rights reserved. 2015 Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(15)60454-8 ;PMID: 26049252 ;CODEN: LANCAO

Full text available

Citations Cited by
15
Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial
Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial
Material Type:
Article 		Add to My Research

Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial

The Lancet (British edition), 2020-05, Vol.395 (10237), p.1613-1626 [Peer Reviewed Journal]

2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license ;Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. ;2020. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. This work is published under https://creativecommons.org/licenses/by/3.0/ (theLicense”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license 2020 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(20)30932-6 ;PMID: 32580883

Full text available

Citations Cited by
16
Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study
Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study
Material Type:
Article 		Add to My Research

Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study

The Lancet (British edition), 2021-05, Vol.397 (10285), p.1646-1657 [Peer Reviewed Journal]

2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license ;Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. ;2021. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. This work is published under https://creativecommons.org/licenses/by/3.0/ (theLicense”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license 2021 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(21)00677-2 ;PMID: 33901420

Full text available

Citations Cited by
17
Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study
Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study
Material Type:
Article 		Add to My Research

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

The Lancet, 2020-02, Vol.395 (10223), p.507-513 [Peer Reviewed Journal]

2020 Elsevier Ltd ;Copyright © 2020 Elsevier Ltd. All rights reserved. ;2020. Elsevier Ltd ;2020. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.elsevier.com/legal/elsevier-website-terms-and-conditions ;2020 Elsevier Ltd. All rights reserved. 2020 Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(20)30211-7 ;PMID: 32007143

Digital Resources/Online E-Resources

Citations Cited by
18
COVID-19 pandemic and admission rates for and management of acute coronary syndromes in England
COVID-19 pandemic and admission rates for and management of acute coronary syndromes in England
Material Type:
Article 		Add to My Research

COVID-19 pandemic and admission rates for and management of acute coronary syndromes in England

The Lancet (British edition), 2020-08, Vol.396 (10248), p.381-389 [Peer Reviewed Journal]

2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license ;Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. ;2020. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. This work is published under https://creativecommons.org/licenses/by/3.0/ (theLicense”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license 2020 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(20)31356-8 ;PMID: 32679111

Full text available

Citations Cited by
19
Infective endocarditis
Infective endocarditis
Material Type:
Article 		Add to My Research

Infective endocarditis

The Lancet (British edition), 2016-02, Vol.387 (10021), p.882-893 [Peer Reviewed Journal]

Elsevier Ltd ;2016 Elsevier Ltd ;Copyright © 2016 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Feb 27, 2016 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(15)00067-7 ;PMID: 26341945 ;CODEN: LANCAO

Full text available

Citations Cited by
20
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
Material Type:
Article 		Add to My Research

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

The Lancet (British edition), 2021-05, Vol.397 (10289), p.2049-2059 [Peer Reviewed Journal]

2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license ;Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. ;2021. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. This work is published under https://creativecommons.org/licenses/by/3.0/ (theLicense”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license 2021 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(21)00897-7 ;PMID: 34000257

Full text available

Citations Cited by

Results 1 - 20 of 20,037  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Refine My Results

Creation Date 

From To
Refine
  1. Before 1964  (179)
  2. 1964 To 1978  (4,903)
  3. 1979 To 1993  (7,242)
  4. 1994 To 2009  (5,761)
  5. After 2009  (1,958)
  6. More options open sub menu

Subject 

  1. Humans  (20,018)
  2. Life Sciences & Biomedicine  (16,440)
  3. Science & Technology  (16,440)
  4. General & Internal Medicine  (16,437)
  5. Medicine, General & Internal  (16,436)
  6. Middle Aged  (16,214)
  7. Female  (12,964)
  8. Male  (12,904)
  9. Aged  (11,209)
  10. Adult  (10,164)
  11. Biological And Medical Sciences  (4,517)
  12. Medical Sciences  (4,484)
  13. Adolescent  (3,521)
  14. Internal Medicine  (1,849)
  15. Medical Research  (1,749)
  16. Child  (1,690)
  17. Aged, 80 And Over  (1,688)
  18. Patients  (1,660)
  19. Time Factors  (1,416)
  20. Risk Factors  (1,403)
  21. More options open sub menu

Language 

  1. Japanese  (1,332)
  2. Russian  (11)
  3. Norwegian  (7)
  4. Portuguese  (1)
  5. Hungarian  (1)
  6. More options open sub menu
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait